How to Choose a Hormone Optimization Clinic in 2026

Most people searching for a hormone optimization clinic already understand the basics of low testosterone or menopause. They are comparing providers before booking a consultation. The content they find tends to fall into two patterns: telehealth-versus-clinic comparisons, often written by telehealth companies, and generic “red flag” checklists with no clinical sourcing.

A more useful approach sets aside the question of delivery model and applies an objective, guideline-based framework to any provider, whether that provider is a telehealth platform, a med spa, or a brick-and-mortar practice. The framework below draws on Endocrine Society diagnostic criteria, The North American Menopause Society’s (NAMS) 2022 timing-based guidance, and the FDA’s 2026 label change.

The need for a clear standard is growing. The testosterone therapy subscription market was valued at $3.8 billion in 2025 and is projected to reach $9.4 billion by 2034, according to industry research. More options also bring more noise.

Why the Standard Advice Falls Short

Many comparison posts come from telehealth-first companies that have a structural reason to steer readers toward their own model, even when they acknowledge its limits. Red-flag lists are repeated almost word for word across sites, and they rarely cite the clinical guidelines behind them.

Quality does not depend on whether a visit happens in person or by video. It depends on whether a clinic performs a proper clinical evaluation and then follows up. A CBS News investigation found telehealth sites promoting testosterone for indications not on the FDA label, including vague claims about “male menopause,” even though the FDA bans off-label advertising. Cases like this show why guideline-based criteria should drive the decision more than channel type.

The Five Criteria: An Evidence-Based Framework for Evaluating Any Provider

The five criteria below come from Endocrine Society, NAMS, ACOG, and FDA sources, and they apply to any provider. Each section covers the relevant guidance and offers a question to ask during a consultation.

Criterion 1: Diagnosis Confirmed by Lab-Based Testing, Not a Single At-Home Test

The Endocrine Society recommends diagnosing hypogonadism only in men who have both symptoms and signs of deficiency and unequivocally and consistently low testosterone. That finding should be confirmed by repeating a fasting morning total testosterone measurement using an accurate assay.

Testosterone levels fluctuate, so a single finger-stick or at-home result does not meet this standard. A legitimate baseline panel includes total testosterone, free testosterone, estradiol, a complete blood count, a metabolic panel, and PSA where appropriate.

Question to ask: “How many separate measurements, and under what conditions, confirmed this diagnosis?”

Criterion 2: A Defined Monitoring Cadence After Treatment Begins

Endocrine Society guidance calls for measuring testosterone and hematocrit at 3 to 6 months, at 12 months, and annually after that. Prostate safety follows a parallel schedule: PSA evaluation and a digital prostate examination at baseline and again 3 to 12 months after therapy begins.

Monitoring is an ongoing commitment, and a single consult does not satisfy it. Patients can ask for the follow-up schedule in writing before starting treatment. As subscription models grow, the sign-up process matters less than the follow-up system behind it: labs ordered, results reviewed, and doses adjusted.

Criterion 3: In-Person Safety Gates, Such as the Hematocrit Stop-and-Reassess Protocol

If hematocrit rises above 54%, guidelines call for stopping therapy until it falls to a safe level, evaluating for hypoxia and sleep apnea, and then restarting at a reduced dose. Elevated hematocrit raises clotting risk, and a clinic can only catch it through a lab draw and a clinician’s interpretation, neither of which a questionnaire can provide.

The TRAVERSE trial (5,246 participants, mean follow-up of 33 months) found that transdermal testosterone was non-inferior to placebo for major adverse cardiovascular events in men with documented hypogonadism, though it also found higher rates of atrial fibrillation, pulmonary embolism, and acute kidney injury. Cleveland Clinic commentary notes that these findings apply only to appropriately diagnosed patients and do not extend to men treated outside clinical indications.

Question to ask: “Is there a written protocol for elevated hematocrit, and what in-person capability exists to act on it?”

Criterion 4: Individualized, Timing-Based Counseling for Women, Not a Standardized Online Protocol

NAMS’s 2022 position statement concludes that for most healthy, symptomatic women under 60 or within 10 years of menopause onset, the benefits of hormone therapy outweigh the risks. For women who start more than 10 years after menopause onset or after age 60, the benefit-risk ratio is less favorable because of higher absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia.

On February 12, 2026, the FDA approved labeling changes for six menopausal hormone therapy products. The changes removed references to cardiovascular disease, breast cancer, and probable dementia from the boxed warning. The boxed warning for endometrial cancer risk remains for estrogen-only systemic products used by women with an intact uterus.

The label change makes individualized risk counseling more important; it does not replace that counseling. A standardized intake form cannot weigh a woman’s age, years since menopause, and personal risk factors.

Question to ask: “How does this clinic factor in my age and years since menopause, rather than applying one protocol to everyone?”

Criterion 5: Transparency About Compounded Versus FDA-Approved Formulations

The 2026 label change applies only to approved menopausal hormone therapy products. Compounded bioidentical hormone therapy remains unapproved by the FDA, and the update gives it no approval status. ACOG states that compounded bioidentical menopausal hormone therapy “should not be prescribed routinely when FDA-approved formulations exist.”

Quality concerns about compounded products are well documented. A 2021 study in the Journal of Clinical Pharmacology found that 34.5% of tested compounded samples fell outside the acceptable potency range, with some containing as little as 67.5% of the intended dose. Oversight is also uneven: a 2023 review found that a supervising doctor was not on-site at 81.8% of med spas. In January 2026, New York’s Department of State warned that hormone replacement therapy must be performed by licensed professionals under physician or nurse practitioner supervision.

A transparent provider will state plainly, before a patient commits, whether a prescription is FDA-approved or compounded, and explain the reason.

Putting the Framework to Work: Questions to Bring to Any Consultation

• How was my diagnosis confirmed, and with how many measurements?
• What is the written monitoring schedule?
• What happens if my hematocrit exceeds safe limits?
• (For women) How are my age and time since menopause factored into my risk?
• Is my prescription FDA-approved or compounded, and why?

Supporting due-diligence questions:

• Is baseline blood work required before prescribing?
• Are the prescribing clinicians clearly identified?
• Are pricing, cancellation, and pause or adjustment terms explained before payment?
• Which pharmacy dispenses the medication?

These questions work for any delivery model, and their purpose is to assess clinical rigor.

What This Framework Looks Like in Practice

Providers that meet all five criteria tend to share certain traits: in-person lab draws and physical exams, clinical oversight, a documented follow-up calendar, and openness about formulations.

Red Mountain is one example of a practice built this way. It has more than 30 years of patient outcomes and a network of brick-and-mortar clinics with in-person providers. It does not operate as an app-only model, and its proprietary programs have been refined over decades. Within Red Mountain’s care model, hormone optimization belongs to the “Function” stage, where the goal is restoring how the body works. It is one tool among several, paired with ongoing monitoring and longevity-focused follow-up rather than a one-time prescription.

Conclusion: Choosing on Criteria, Not Convenience Alone

Convenience and delivery model are not the right basis for this decision; clinical rigor is. Five criteria hold up regardless of how the market changes:

1. Confirmed lab-based diagnosis
2. A defined monitoring cadence
3. In-person safety gates
4. Individualized, timing-based counseling for women
5. Transparency about formulations

As the market grows and regulatory language shifts, individualized, guideline-based care becomes more important.

Next Step: Bringing This Framework to a Consultation

Readers can bring these five criteria to their next consultation, wherever they choose to be seen. This is the kind of evaluation Red Mountain’s clinicians walk patients through in person, drawing on decades of clinician-led care. An informed decision will serve a patient better than a quick one.